-
NKGen Biotech NasdaqGM:NKGN NKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. Its lead products include SNK01, an autologous NK cell therapy candidate treatment for neurodegenerative diseases; and SNK02, an allogeneic NK cell therapy, which is in Phase 1 clinical trials for refractory solid tumors. The company has a license agreement with NKMAX. The company was formerly known as NKMAX America, Inc. NKGen Biotech, Inc. was founded in 2017 and is headquartered in Santa Ana, California.
Location: 3001 Daimler Street, Santa Ana, CA, 92705, United States | Website: https://nkgenbiotech.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
46.45M
Cash
8.00K
Avg Qtr Burn
-5.217M
Short % of Float
12.55%
Insider Ownership
70.80%
Institutional Own.
1.66%
Qtr Updated
09/30/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Troculeucel (SNK01) Details Alzheimer's disease | Phase 1/2 Data readout | |
SNK01 Details Parkinson's disease, Neurodegenerative disease | Phase 1/2 Initiation | |
SNK02 Details Solid tumor/s, Cancer | Phase 1 Update | |
Troculeucel (SNK01) Details no known indication | IND Submission |